Who are Tafenoquine Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aubagio, Leflunomide 10 milligram (MG), FLUNIXIN, Teriflunomide HMR1726, Leflunomide plus Methotrexate, Leflunomide(LEF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tafenoquine-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tafenoquine Oral Tablet — Competitive Intelligence Brief

Tafenoquine Oral Tablet (Tafenoquine Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 8-aminoquinoline. Area: Infectious Diseases.

phase 3 8-aminoquinoline dihydroorotate dehydrogenase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Tafenoquine Oral Tablet (Tafenoquine Oral Tablet) — State University of New York - Upstate Medical University. Tafenoquine is an antimalarial drug that works by targeting the Plasmodium parasite's heme detoxification pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tafenoquine Oral Tablet TARGET	Tafenoquine Oral Tablet	State University of New York - Upstate Medical University	phase 3	8-aminoquinoline	dihydroorotate dehydrogenase
Aubagio	TERIFLUNOMIDE	Sanofi	marketed	Pyrimidine Synthesis Inhibitor [EPC]	dihydroorotate dehydrogenase	2012-01-01
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)
FLUNIXIN	FLUNIXIN		marketed		Dihydroorotate dehydrogenase (quinone), mitochondrial
Teriflunomide HMR1726	Teriflunomide HMR1726	Sanofi	marketed	Dihydroorotate dehydrogenase inhibitor; immunosuppressant	Dihydroorotate dehydrogenase (DHODH)
Leflunomide plus Methotrexate	Leflunomide plus Methotrexate	Bangladesh Medical University	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Dihydroorotate dehydrogenase (leflunomide); Dihydrofolate reductase (methotrexate)
Leflunomide(LEF)	Leflunomide(LEF)	Nanjing Children's Hospital	marketed	Immunosuppressant; DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (8-aminoquinoline class)

GlaxoSmithKline · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
State University of New York - Upstate Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tafenoquine Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/tafenoquine-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab